Janssen Pharmaceutical Companies (Johnson & Johnson) is an American pharmaceutical company with a significant neuroscience portfolio focused on developing disease-modifying therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders[1].
| Attribute | Value |
|---|---|
| Founded | 1953 (Janssen Pharmaceutica) |
| Headquarters | Beerse, Belgium / Raritan, New Jersey, USA |
| Parent | Johnson & Johnson |
| CEO | Joaquin Duato (J&J Global) |
| Market Cap | ~$400B (J&J, 2025) |
| Employees | ~40,000 (Janssen) |
| R&D Budget | ~$15B annually (J&J total) |
| Drug | Mechanism | Stage | Status |
|---|---|---|---|
| JNJ-63733657 | Anti-tau monoclonal antibody | Phase 2 | TauClear program |
| JNJ-2056 | Tau aggregation inhibitor | Phase 1 | Licensed from Cognition Therapeutics |
| ACI-35 | Tau vaccine | Phase 1b | Partnered with AC Immune |
| ACI-35.030 | Next-gen tau vaccine | Preclinical | Enhanced immunogenicity |
JNJ-63733657 is a humanized monoclonal antibody designed to target and clear pathological tau protein aggregates. Tau pathology correlates strongly with cognitive decline in Alzheimer's disease, making this a key strategic program for Janssen[2].
Mechanism:
Clinical Development:
JNJ-2056 is a tau aggregation inhibitor licensed from Cognition Therapeutics. The small molecule prevents the formation of toxic tau oligomers and fibrils, representing a disease-modifying approach[2:1].
Mechanism:
Janssen partners with AC Immune on the ACI-35 liposomal tau vaccine program. This represents a novel vaccination approach targeting phosphorylated tau epitopes[3].
Mechanism:
| Drug | Mechanism | Stage | Status |
|---|---|---|---|
| JNJ-67853737 | Alpha-synuclein antibody | Phase 1 | First-in-human |
| JNJ-79401585 | LRRK2 inhibitor | Discovery | Preclinical |
| JNJ-4232 | adenosine A2A receptor antagonist | Phase 2 | Completed |
JNJ-67853737 is an anti-alpha-synuclein monoclonal antibody targeting the pathogenic aggregation of alpha-synuclein, the key protein implicated in Parkinson's disease and Lewy body dementia.
Mechanism:
Clinical Development:
JNJ-79401585 is a LRRK2 (leucine-rich repeat kinase 2) inhibitor targeting the most common genetic cause of Parkinson's disease. LRRK2 mutations account for 5-10% of familial PD and 1-3% of sporadic PD.
Mechanism:
| Drug | Indication | Mechanism | Stage |
|---|---|---|---|
| JNJ-64042056 | Epilepsy | Ion channel modulator | Phase 1 |
| JNJ-6880 | ALS | SOD1 antibody | Discovery |
| JNJ-5405 | MS | Immune modulation | Discovery |
| NfL Assay | Alzheimer's/Parkinson's | Biomarker | Commercial |
Janssen's partnership with AC Immune (Switzerland) focuses on tau-targeted therapies. The collaboration includes:
License agreement for JJN-2056, a tau aggregation inhibitor representing an oral small molecule approach to tau pathology.
Historical collaborations on Alzheimer's research, including biomarker development and clinical trial methodologies.
Various CNS programs spanning psychiatry, neurology, and rare diseases. Janssen retains options on certain programs.
Janssen has prioritized tau-targeted therapies based on:
The company employs biomarker strategies including:
Janssen is exploring:
| Metric | Value |
|---|---|
| Janssen Revenue | $56B |
| J&J Total Revenue | $89B |
| J&J R&D Investment | $15B |
| Neuroscience Share | ~12% of pharma |
Janssen represents the largest segment of Johnson & Johnson's pharmaceutical business, with neuroscience being a key growth area despite competitive pressures in the Alzheimer's space.
Janssen was founded in 1953 by Dr. Paul Janssen in Beerse, Belgium. Known for its pioneering drug discovery, the company became part of Johnson & Johnson in 1961. Under J&J, Janssen grew to become one of the world's largest pharmaceutical companies.